Leiomyosarcoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions.
Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure, and radiation exposure. Treatment includes chemotherapy, radiation therapy, and surgery.
The Leiomyosarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Leiomyosarcoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 65 molecules, with 63 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Leiomyosarcoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Leiomyosarcoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Leiomyosarcoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncADC Therapeutics SA
Advenchen Laboratories LLC
Agenus Inc
Akeso Inc
Alphamab Oncology
ANTUREC Pharmaceuticals GmbH
APIM Therapeutics AS
AstraZeneca Plc
Aulos Bioscience Inc
BeiGene Ltd
BioAtla Inc
BioInvent International AB
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cebiotex SL
Centrymed Pharmaceutical Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Children's Research Institute
Eisai Co Ltd
Elevar Therapeutics Inc
Eli Lilly and Co
EpicentRx Inc
Eucure (Beijing) Biopharma Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Highlight Therapeutics SL
Immix BioPharma Inc
Incyte Corp
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Kineta Inc
Lixte Biotechnology Holdings Inc
Merck & Co Inc
Merck KGaA
Moleculin Biotech Inc
NKGen Biotech Inc
Oncomatryx Biopharma SL
OncoResponse Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
Polaris Pharmaceuticals Inc
PTC Therapeutics Inc
Pyxis Oncology Inc
Recordati SpA
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Tempest Therapeutics Inc
Tessa Therapeutics Ltd
Viracta Therapeutics Inc
Virogin Biotech Ltd
Yooyoung Pharm Co Ltd
Zr Pharma & Gmbh
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Leiomyosarcoma reports